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It was already found that Ang II AT
1
receptors are involved in the neuroadaptative changes induced by a single exposure to
amphetamine, and such changes are related to the development of behavioral and neurochemical sensitization. The induction
of the immediately early gene c-fos has been used to define brain activated areas by amphetamine. Our aim was to evaluate the
participation of AT
1
receptors in the neuronal activation induced by amphetamine sensitization. The study examined the c-fos
expression in mesocorticolimbic areas induced by amphetamine challenge (0.5mg/kg i.p) in animals pretreated with candesartan,
a selective AT
1
receptor blocker (3mg/kg p.o × 5 days), and amphetamine (5mg/kg i.p) 3 weeks before the challenge. Increased
c-fos immunoreactivity was found in response to the amphetamine challenge in the dorsomedial caudate-putamen and nucleus
accumbens, and both responses were blunted by the AT
1
receptor blocker pretreatment. In the infralimbic prefrontal cortex,
increased c-fos immunoreactivity was found in response to amphetamine and saline challenge, and both were prevented by the
AT
1
receptor blocker. No differences were found neither in ventral tegmental area nor prelimbic cortex between groups. Our results
indicate an important role for brain Ang II in the behavioral and neuronal sensitization induced by amphetamine.
1. Introduction
It has been demonstrated that the enhanced responses to
psychostimulants rely on time-dependent neuroadaptations
that involves enduring alterations in behavioral and neuro-
chemical responses. These changes, known as sensitization,
are associated with long-lasting hyperreactivity of the central
dopaminergic mesolimbic pathway [1–3]. Repeated exposure
is not necessary, since a single exposure to psychostimulants
or evenmorphine is sufficient to induce persistent locomotor
sensitization and neurochemical and electrophysiological
changes in rodents [4–6]. In the two-injection protocol,
changes in responsiveness are induced by the first psychos-
timulant administration and are revealed by the second one.
This model is a very simple paradigm and is more sensitive
than the repeated injection protocol to study the bases of
long-term effects of drugs of abuse [5].
One of the principal systems involved in drug abuse is
the dopaminergic mesolimbic system, a critical component
in the brain reward circuit [7]. Brain Angiotensin II (Ang
II) belongs to the group of peptides known to stimulate
dopamine release [8–10]. Moreover, the Ang II receptors
are located in dopamine-rich brain areas [10, 11], such as
the nucleus accumbens (Nacc) and caudate-putamen (CPu),
strongly related to self-administration and sensitization to
drugs of abuse [12].
Sensitization to drugs such as amphetamine is associated
with alterations in the morphology of neurons in the Nacc, a
brain region critical to motivation and reward. It is known
that Ang II is involved in the control of salt appetite, and
the sodium depletion that promotes salt appetite also leads
to alterations in neurons in the Nacc. In this sense, the
medium spiny neuronswithin the shell of theNacc of rats that
had experienced sodium depletions had significantly more
dendritic branches and spines than controls [13]. In addition,
a history of sodium depletion was found to have cross-
sensitization effects, leading to enhanced psychostimulant
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responses to amphetamine [14]. Thus, common neuroadap-
tations in response to salt and amphetamine may provide a
general mechanism for the enhanced responses induced by
reexposure to these challenges.
In a previous work, we showed that Ang II AT
1
receptors
were involved in the neuroadaptative changes induced by a
single exposure to amphetamine and that such changes were
related to the development of behavioral and neurochemical
sensitization [6].
The induction of immediately early gene c-fos is a well-
accepted marker of neuronal activation, and this approach
has been used to define areas involved in the actions induced
by amphetamine, since enhanced c-fos expression in theCPu,
Nacc, prefrontal cortex (PFC), and ventral tegmental area
(VTA) was found after amphetamine administration [15].
In order to extend our previous findings, we evaluated
the participation of AT
1
receptors in the neuronal activa-
tion induced by amphetamine sensitization in the nucleus
accumbens core and shell (Nacc core, Nacc shell), CPu,
PFC, and VTA. Experiments were performed using the
same protocols and doses of AT
1
receptor blocker and
amphetamine in a context-independent manner previously
used [6]. Although the contextual environment strengthens
the expression of sensitized responses when tested in the
context previously associated with drug administration [16],
it has been shown that amphetamine induced sensitization
with the two-injection protocol in both context-dependent
and in context-independent manner, while cocaine induced
sensitization in context-dependentmanner [5]. In the present
study, the amphetamine administrations were performed
in different environments to induce responses in context-
independent conditions. To our knowledge, this is the first
study that aims to analyze the involvement of brain Ang II in
altered neuronal activation using the two-injection protocol
of amphetamine administration in a context-independent
manner.
2. Materials and Methods
2.1. Animals. Adult male Wistar rats (250–330 g), purchased
from the Facultad de Ciencias Veterinarias (Universidad
Nacional de La Plata, Buenos Aires, Argentina), were used
in this study. Animals were maintained at 20–24∘C under
a 12 h light-dark cycle (lights on at 0700 hours) with free
access to food andwater. Upon arrival, theywere placed in the
colony room for at least 7 days before experimental tests and
randomly housed in groups of four per cage. All procedures
were approved by the Animal Care and Use Committee of
the Facultad de Ciencias Quı´micas, Universidad Nacional de
Co´rdoba, Argentina, in accordance with the NIH Guide for
the Care and Use of Laboratory Animals.
2.2. Experimental Procedure. The animals received candesar-
tan cilexetil 3mg/kg or vehicle by oral administration (intra-
gastric using a feeding needle) once a day during 5 days.
Twenty-four hours after the last administration, they were
injected with D-amphetamine 5mg/kg or saline i.p. A total
of 33 animals were assigned randomly to the treatments:
vehicle-saline (veh-sal), vehicle-amphetamine (veh-amph),
candesartan-saline (cv-sal), and candesartan-amphetamine
(cv-amph), and they were left undisturbed in their home
cages until the day of the experiment. Twenty-one days
after pretreatment, amphetamine-induced neuronal activa-
tion was evaluated in the four groups using a challenge
injection of amphetamine 0.5mg/kg i.p.This second injection
of the psychostimulant was given in a different environment
to avoid context association with the drug. To discriminate
the response to amphetamine challenge, another group of 20
animals were assigned randomly to the same four treatments
and tested after a challenge injection of saline.
2.3. Staining Procedure for Fos and Fos/Tyrosine Hydroxylase
(TH) Immunohistochemistry. Fos immunoreactivity assay
was performed in Nacc core, Nacc shell, CPu, PFC, and VTA.
The double-labeling with Fos/TH antibodies was performed
only in VTA in order to identify differential activation in
catecholaminergic neurons since dopaminergic neurons in
this nucleus send projections to Nacc and prefrontal cortex.
Ninetyminutes after the amphetamine or saline challenge
injection, the animals were prepared for brain fixation for
immunohistochemical detection of Fos or Fos and TH. This
approachwas selected because the increased formation of Fos
protein, 1 to 2 h after stimulation, correlates with increased
neural activity in a wide range of neural systems [17, 18].
The animals were anesthetized with chloral hydrate 16%
(400mg/kg i.p.) and perfused transcardially with 250mL of
normal saline and heparine (200 𝜇L/L), followed by 400mL
of 4% paraformaldehyde in 0.1M phosphate buffer (PB, pH
7.4). The brains were removed, fixed in the same solution
overnight, and then stored at 4∘C in PB containing 30%
sucrose. Coronal sections of 40 𝜇m were cut using a freezing
microtome (Leica CM15105) and collected in PB 0.01M.They
were placed in amixture of 10%H
2
O
2
and 10%methanol until
oxygen bubbles ceased appearing. Samples were incubated in
10% normal horse serum (NHS) (GIBCO, Auckland, NZ) in
PB for 2 h to block nonspecific binding sites.
All of the free-floating sections from each brain were first
processed for Fos immunoreactivity (Fos-IR) using an avidin
biotin-peroxidase procedure. Sections of the VTA were then
stained for TH immunoreactivity (TH-IR).
The staining procedures followed the double-labeling
procedures described in Franchini and Vivas [19] and Fran-
chini et al. [20]. Briefly, the free-floating sections were
incubated overnight at room temperature in a rabbit anti-
fos antibody (produced in rabbits against a synthetic 14-
amino acid sequence, corresponding to residues 4–17 of
human Fos) (Ab-5; Oncogene Science, Manhasset, NY),
diluted 1 : 20,000 in PB containing 2% NHS and 0.3% Triton
X-100 (Flucka Analytical). The sections were then rinsed
with PB 0.01M and incubated with biotin-labeled univer-
sal secondary antibody (diluted 1 : 2,000 in 2% NHS-PB)
and avidin-biotin-peroxidase complex (Vector Laboratories,
Burlingame, CA; diluted 1 : 200 in 2% NHS-PB), for 2 h each
at room temperature. The peroxidase label was detected with
diaminobenzidine hydrochloride (Sigma Chemical Co.); the
solutionwas intensifiedwith 1% cobalt chloride and 1% nickel
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ammonium sulfate. This method produces a violet nuclear
reaction product.
The Fos-labeled sections, also processed for immunocy-
tochemical localization of TH, were rinsed and incubated
in 10% NHS in PB for 2 h. Immediately after, they were
incubated for 48 h at 4∘C with monoclonal TH antibody
(Millipore, Tecnolab S.A., diluted 1 : 5,000 in PBwith 2%NHS
and 0.3% Triton X-100). After incubation, the sections were
rinsed and incubated with biotin-labeled mouse secondary
antibody (Jackson Laboratories (P) Ltd., diluted 1 : 5,000
in 2% NHS-PB) and avidin-biotin-peroxidase complex, for
2 h each at room temperature. Cytoplasmic TH-IR was
detected by unintensified diaminobenzidine hydrochloride,
which produces a brown reaction product. Finally, the free-
floating sections were mounted on gelatinized slides, air-
dried overnight, dehydrated, cleared in xylene, and placed
under a coverslip with DPX mountant for histology (Flucka
Analytical).
2.4. Cytoarchitectural andQuantitative Analysis. Images con-
taining Fos-IR nuclei were obtained by using a computer-
ized system that included a Leica DM 4000 B microscope
equipped with a DFC Leica digital camera attached to a
contrast enhancement device. The brain nuclei evidencing
Fos-IR were identified and delimited according to atlas of
Paxinos [21]. The Fos-IR nuclear profiles were counted at the
dorsomedial region of CPu (corresponding to plates with a
distance of 2.28mm to 1.92mm from bregma), Nacc core and
shell (corresponding to plates with a distance of 2.28mm to
1.92mm from bregma), PFC (corresponding to plates with
a distance of 3.72mm to 3.00mm from bregma), and VTA
(corresponding to plates with a distance of −6.24mm to
−6.48mm from bregma). The brain sections were processed
concurrently for subjects across all groups. Images were stan-
dardized using Adobe Photoshop image analysis program
(version 5.5). Counting of Fos-IR was accomplished using
IMAGE J software from the National Institutes of Health
(NIH). Threshold was fixed between an interval of 0 and 150
in black and white conditions, and all higher values were
considered background. Fos-IR neurons were identified by
dense black staining of the nucleus and counted by setting
a size range for cellular nuclei (8 to 12𝜇m of diameter).
Themeasurement for each brain area was done bilaterally
in two sections. The value obtained was the average of the
four countings. The counting was made on a 0.37mm2 area
(corresponding to 200x magnification) in animals of each
condition for amphetamine challenge (5–8 animals) and for
saline challenge (4-5 animals). Because the size and section
thickness of nuclei did not change between experimental and
control groups, any systematic error should be identical for
all groups. Hence, the results are meant to provide relative
data on expression of Fos-IR but are not meant to be accurate
estimates of absolute cell counts. The counting was made
by two operators on each section analyzed, to ensure that
the number of profiles obtained was similar, but only one
counting was used. Counting of Fos-IR cells was performed
blinded to the experimental groups.
2.5. Double Immunostaining Fos/TH Quantification. Fos-IR
nuclei (violet) were identified and counted only in positive
TH cells labeled by brown. The counting was performed in
VTA in two sections (corresponding to plates with a distance
of −6.24 to −6.48mm from bregma) under microscope.
2.6. Statistical Analysis. Data were reported as means ±
SEM. The study design used three-way ANOVA with vehi-
cle and candesartan as pretreatment factor; saline and
amphetamine as treatment factor; and challenge with saline
or amphetamine as the third factor analyzed. If an interaction
and/or main effect was observed, pair-wise comparisons
following ANOVAwere made using the Bonferroni post test.
A value of 𝑃 < 0.05 was considered significant. The analysis
was performed using STATISTICA 7 software.
3. Results
3.1. Distribution of Fos in the Dorsomedial Region of Caudate
Putamen, Nucleus Accumbens Core and Shell. As shown
in Figure 1, the amphetamine challenge induced a signif-
icant increase in the number of Fos-IR cells in vehicle-
amphetamine rats compared to controls (vehicle-saline and
candesartan-saline groups) within three areas of analy-
sis: CPu (Figure 1(a)), Nacc core (Figure 1(b)), and Nacc
shell (Figure 1(c)). Pretreatment with candesartan signifi-
cantly prevented the increase in number of Fos-IR cells in
amphetamine-treated rats within these three areas.
CPu: the results obtained from the three-way ANOVA
analysis were PRETREATMENT 𝐹
(1,39)
= 6.69, 𝑃 < 0.01,
TREATMENT 𝐹
(1,39)
= 8.45, 𝑃 < 0.006, CHALLENGE
𝐹
(1,39)
= 43.55, 𝑃 < 0.000001, INTERACTION pretreatment
∗ challenge 𝐹
(1,39)
= 6.35, 𝑃 < 0.02, INTERACTION treat-
ment ∗ challenge 𝐹
(1,39)
= 11.58, 𝑃 < 0.002, and INTERAC-
TION pretreatment ∗ treatment ∗ challenge 𝐹
(1,39)
= 8.17,
𝑃 < 0.007. Bonferroni post hoc comparisons indicated that
the veh-amph group was significantly different from the veh-
sal (𝑃 < 0.00005), cv-sal (𝑃 < 0.000001), and the cv-amph
groups (𝑃 < 0.0003) after amphetamine challenge. Rep-
resentative microphotographs are shown in Figure 3 (C
1
to
F
1
). Saline challenge did not produce significant differences
in the Fos-IR cells pattern between treatments in this area
(Figure 1(a)).
Nacc core: the results obtained from the three-way
ANOVA analysis were PRETREATMENT 𝐹
(1,39)
= 12.28,
𝑃 < 0.001, TREATMENT 𝐹
(1,39)
= 10.14, 𝑃 < 0.003, CHAL-
LENGE 𝐹
(1,39)
= 5.36, 𝑃 < 0.03, and INTERACTION pre-
treatment ∗ treatment 𝐹
(1,39)
= 5.07, 𝑃 < 0.03. Bonferroni
post hoc comparisons indicated that the veh-amph group
was significantly different from the veh-sal (𝑃 < 0.0006),
cv-sal (𝑃 < 0.00003) and from the cv-amph groups (𝑃 <
0.0004) after amphetamine challenge. Representative micro-
photographs are shown in Figure 3 (C
2
to F
2
). Saline
challenge did not produce significant differences in the Fos-
IR cells pattern between treatments in this area (Figure 1(b)).
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(c) Nucleus accumbens shell
Figure 1: Average number of Fos-IR neurons in brain nuclei: dorsomedial region of CPu (a), Nacc core (b), andNacc shell (c), in response to a
challenge of saline (𝑛 = 4-5) or amphetamine (𝑛 = 5–8), 21 days after a pretreatment with cv or veh and a treatment with amph or sal (veh-sal,
cv-sal, veh-amph, and cv-amph). Values are means ± SEM. ∗𝑃 < 0.05 significantly different from the other amphetamine-challenged groups
(3-way ANOVA, post hoc Bonferroni).
Nacc shell: the results obtained from the three-way
ANOVA analysis were PRETREATMENT 𝐹
(1,39)
= 7.16, 𝑃 <
0.01, TREATMENT 𝐹
(1,39)
= 17.58, 𝑃 < 0.0002, CHAL-
LENGE 𝐹
(1,39)
= 10.07, 𝑃 < 0.003, INTERACTION pre-
treatment ∗ treatment 𝐹
(1,39)
= 6.79, 𝑃 < 0.01, and INTER-
ACTION treatment ∗ challenge 𝐹
(1,39)
= 7.61, 𝑃 < 0.009.
Bonferroni post hoc comparisons indicated that the veh-
amph group was significantly different from the veh-sal (𝑃 <
0.000007), cv-sal (𝑃 < 0.000006), and the cv-amph groups
(𝑃 < 0.0003) after amphetamine challenge. Representative
microphotographs are shown in Figure 3 (C
3
to F
3
). Saline
challenge did not produce significant differences in the Fos-
IR cells pattern between treatments in this area (Figure 1(c)).
3.2. Distribution of Fos in the Infralimbic and Prelimbic
Cortex. Infralimbic cortex (IL): as shown in Figure 2(a),
saline and amphetamine challenges induced a signifi-
cant increase in the number of Fos-IR cells in vehicle-
amphetamine rats compared to controls (vehicle-saline and
candesartan-saline groups). Pretreatment with candesartan
significantly prevented the increase in number of Fos-IR
cells in amphetamine-treated rats within this brain area. The
results obtained from the three-way ANOVA analysis were
PRETREATMENT 𝐹
(1,28)
= 5.51, 𝑃 < 0.03, TREATMENT
𝐹
(1,28)
= 11.83, 𝑃 < 0.002, CHALLENGE 𝐹
(1,28)
= 1.53, 𝑃 =
0.22, and INTERACTION pretreatment ∗ treatment 𝐹
(1,28)
=
5.40, 𝑃 < 0.03. Bonferroni post hoc comparisons indicated
that the veh-amph group was significantly different from the
veh-sal (𝑃 < 0.003), cv-sal (𝑃 < 0.001), and the cv-amph
groups (𝑃 < 0.01) independently of the challenge received.
Representative microphotographs are shown in Figure 4 (C
1
to F
1
).
Prelimbic cortex: no significant differences between
groups were found in this region of the prefrontal cortex.
The results obtained from the three-way ANOVA analysis
were PRETREATMENT 𝐹
(1,34)
= 0.91, 𝑃 = 0.35, TREAT-
MENT 𝐹
(1,34)
= 3.30, 𝑃 = 0.08, and CHALLENGE 𝐹
(1,34)
=
6.75, 𝑃 < 0.01, and no interaction between factors
were found. Bonferroni post hoc comparison indicated that
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(c) Ventral tegmental area-total neurons
Figure 2: Average number of Fos-IR neurons in brain nuclei: IL cortex (a), VTA (c), in response to a challenge of saline (𝑛 = 4-5) or
amphetamine (𝑛 = 5–8), 21 days after a pretreatment with cv or veh and a treatment with amph or sal (veh-sal, cv-sal, veh-amph, and cv-
amph). Values are means ± SEM. ∗𝑃 < 0.05 significantly different from the other groups in response to the same challenge (3-way ANOVA,
post hoc Bonferroni). Average number of Fos/TH-IR neurons in VTA (b), in response to a challenge of saline (𝑛 = 4-5) or amphetamine
(𝑛 = 5–8), 21 days after a pretreatment with cv or veh and a treatment with amph or sal (veh-sal, cv-sal, veh-amph and cv-amph). Values are
means ± SEM. ∗𝑃 < 0.05 significantly different from the salin-challenged groups (3-way ANOVA, post hoc Bonferroni).
amphetamine challenged groups were significantly different
from saline challenged groups (𝑃 < 0.02). Data not shown.
3.3. Distribution of Fos and Fos/TH in the Ventral Tegmental
Area. No differences were found in the number of Fos/TH-
IR double-labeled (Figure 2(b)) and Fos-IR (Figure 2(c))
neurons at VTA, following neither saline nor amphetamine
challenge. Fos/TH-IR: amphetamine challenge did not pro-
duce differences in the activation pattern of VTA neurons
in vehicle-amphetamine rats compared to controls (vehicle-
saline and candesartan-saline groups). No significant dif-
ferences were observed between vehicle-amphetamine and
candesartan-amphetamine groups. Representative micro-
photographs are shown in Figure 4 (C
2
to F
2
). Saline chal-
lenge did not produce significant differences in the Fos/TH-
IR cells pattern between treatments in VTA (Figure 2(b)).
The results obtained from the three-way ANOVA anal-
ysis were PRETREATMENT 𝐹
(1,36)
= 0.01, 𝑃 = 0.91,
TREATMENT 𝐹
(1,36)
= 0.14, 𝑃 = 0.71, and CHALLENGE
𝐹
(1,36)
= 1.30, 𝑃 = 0.26.
Fos-IR: amphetamine challenge did not produce differ-
ences in the activation pattern of VTA neurons in vehicle-
amphetamine rats compared to controls (vehicle-saline and
candesartan-saline groups). No significant differences were
observed between vehicle-amphetamine and candesartan-
amphetamine groups. Representative microphotographs are
shown in Figure 4 (C
2
to F
2
). Saline challenge did not produce
significant differences in the Fos-IR cells pattern between
groups in VTA (Figure 2(c)).
The results obtained from the three-way ANOVA analysis
were PRETREATMENT 𝐹
(1,36)
= 0.37, 𝑃 = 0.54, TREAT-
MENT 𝐹
(1,36)
= 1.25, 𝑃 = 0.27, CHALLENGE 𝐹
(1,36)
= 14.07,
𝑃 < 0.0006. Bonferroni post hoc comparison indicated that
amphetamine challenged groups were significantly different
from saline challenged groups (𝑃 < 0.0006).
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Figure 3: (A) Schematic coronal slice indicating the regionwhere the countingwas done in different areas: CPu (A
1
), Nacc core (A
2
), andNacc
shell (A
3
). (B) Photomicrographs 100x magnification: CPu (B
1
), Nacc core (B
2
), and Nacc shell (B
3
). Photomicrographs 200x magnification
showing the pattern of Fos-IR neurons after an amphetamine challenge in (C) veh-sal group in different areas: CPu (C
1
), Nacc core (C
2
), and
Nacc shell (C
3
); (D) veh-amph group in CPu (D
1
), Nacc core (D
2
), and Nacc shell (D
3
); (E) cv-sal group in CPu (E
1
), Nacc core (E
2
), and
Nacc shell (E
3
); and (F) cv-amph group in CPu (F
1
), Nacc core (F
2
), and Nacc shell (F
3
). Scale bar = 100 𝜇m.
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Figure 4: (A) Schematic coronal slice indicating the region where the counting was done in different areas: IL cortex (A
1
), VTA (A
2
).
(B) Photomicrographs 100x magnification: IL cortex (B
1
) and VTA (B
2
). Photomicrographs 200x magnification of the pattern of Fos-IR
neurons in IL cortex or Fos/TH-IR neurons in VTA after an amphetamine challenge in (C) veh-sal group in different areas: IL cortex (C
1
),
VTA (C
2
); (D) veh-amph group in IL cortex (D
1
), VTA (D
2
); (E) cv-sal group in IL cortex (E
1
), VTA (E
2
); and (F) cv-amph group in IL cortex
(F
1
), VTA (F
2
). A section of each photomicrographs of Fos/TH-IR (indicated by a square) is shown in a higher magnification (1,000x). Scale
bar = 100𝜇m.
4. Discussion
The main finding of this work is that Ang II AT
1
receptors
are involved in the long-lasting neurochemical adaptations
induced by a single exposure to amphetamine. These results
are in agreement with previous findings showing the involve-
ment of Ang II AT
1
receptors in behavioral sensitization
using the same protocol of amphetamine treatment in a
context-independent manner [6]. To our knowledge, this is
the first study performed using the two-injection protocol
of amphetamine administration in a context-independent
manner that aims to analyze the involvement of brain Ang II
in the altered neuronal activation induced by amphetamine
exposure.
Considering that repeated exposure to psychostimulants
is not necessary for development of sensitization, since a
single exposure is sufficient to induce persistent locomotor
sensitization and neurochemical changes, in this study we
used the two-injection protocol of amphetamine. Moreover,
the protocols used for repeated drugs of abuse adminis-
tration elicit different biochemical and cellular responses
than single exposures, which could hamper the subsequent
interpretation of causality links [5]. Then, with the protocol
of amphetamine administration used in the present work,
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the first injection induces the changes in responsiveness and
the second injection unmasks the existence of neuroadapta-
tions [5, 6].
Behavioral sensitization is not limited to addictive drugs,
and it can also be induced by strong motivational or affective
states (thirst or hunger) associated with natural rewards
(water, salt, food, etc.) [22]. Recently, behavioral cross-
sensitization between sodium depletion and cocaine has also
been described [23].The results from these experiments indi-
cate that treatments generating a sustained salt appetite and
producing cocaine-induced psychomotor responses show
reciprocal behavioral cross-sensitization, similar to results
found using amphetamine [14]. In relation to the brain
renin-angiotensin system, it has been found that intracere-
bral administration of Ang II induces sensitization to its
vasoactive effects, such as hypertension sensitization, and
also it could be involved in the development of neuroadaptive
changes related to behavioral sensitization induced by natural
reinforces and drugs of abuse [22]. Moreover, the sensitiza-
tion of sodium appetite and thirst has been associated with
central actions of Ang II and Aldosterone [24].
The induction of immediate early genes, like c-fos, is
a well-accepted marker of neuronal activation, and it has
been used to define brain areas putatively involved in the
actions of amphetamine. Furthermore, dissociation between
c-fos induction and neuronal electrophysiological activation
has also been described [15]. Amphetamine-induced c-fos
expression is quite high in brain areas receiving dopaminergic
innervations, such as theCPu andNacc. Rotllant et al. found a
dose-dependent activation in the Nacc shell and all divisions
of the paraventricular nucleus (PVN) and the amygdala [15].
Moreover, alterations in cellular activity associated with the
expression of amphetamine sensitization in the CPu and
Nacc have been described [7, 18]. Moreover, increased Fos
expression in the Nacc core and shell has been described in
animals with sodiumdepletion submitted to a sham-drinking
paradigm, in which the persistent appetitive behavior and
prolonged ingestion are similar to the behavior of animals
responding to drugs of abuse [25].
In the present study, altered neuronal activation was
found in response to the amphetamine challenge in lim-
bic regions involved in the long-lasting changes associated
with behavioral sensitization [5, 6, 18]. The increased Fos
immunoreactivity induced by amphetamine challenge in
the CPu, Nacc core, and Nacc shell, in animals previously
exposed to amphetamine, was blunted by the AT
1
receptor
antagonist administration. These findings indicate a key role
for brain Ang II in the development of the altered neuronal
activation induced by amphetamine exposure.
Dopaminergic neurotransmission in the Nacc and CPu
plays a critical role in the behavioral effects of psychos-
timulant drugs, and a close relationship has been shown
between Ang II and dopaminergic neurotransmission in
the brain. Functional interactions have also been described
that correlate with anatomical findings showing high AT
1
receptor density in dopamine-rich regions such as the CPu,
hypothalamus, and Nacc [26, 27]. Chronic and single drug
administration leads to behavioral sensitization [28, 29], and
this phenomenon is associated with the sensitized ability to
release dopamine in theNacc andCPu [6, 29, 30].We recently
found that AT
1
receptor blockade blunted the increased
dopaminergic reactivity induced by amphetamine in the
CPu and Nacc, showing a strong influence of Ang II in the
development of this neuroadaptation [6]. Previous in vivo
and in vitro studies support the assumption of a presynaptic
localization of this receptor subtype [8, 26, 31]. Ang II AT
1
receptor activation may be involved in the mechanisms
that underlie the development of increased dopaminergic
reactivity induced by amphetamine, which could be related to
the altered neuronal activation in the CPu andNacc observed
in the present study.
In the PFC, differences in Fos expression in the prelimbic
region were not found. Meanwhile, differences in cellular
activationwere found in the infralimbic region, with a similar
response to both challenges (saline and amphetamine) in
animals previously exposed to amphetamine. In accordance
with these results, previous studies have found an increased
Fos expression in the medial prefrontal cortex, including
the prelimbic and infralimbic regions, in cocaine-sensitized
rats challenged two days after withdrawal [32]. A possible
explanation for the increased neuronal activation to both
challenges in the infralimbic region could be a sensitized
response to stress and not to the psychostimulant, since
there is considerable evidence of cross-sensitization between
drugs of abuse and stress [33]. Interestingly, the AT
1
receptor
blocker prevented this response, corroborating the key role
for Ang II in the stress response extensively described using
AT
1
receptor antagonists [34–38].
The cellular activationwas also analyzed in catecholamin-
ergic neurons in the VTA, and no differences between groups
in response to amphetamine challenge were observed. Acute
amphetamine induced dopamine release in the soma of
dopaminergic neurons; however, Fos expression induced by
acute amphetamine administration (1.5 and 5mg/kg) was
found mostly in GABAergic neurons and very little number
in monoaminergic neurons [15]. It was also found that
chronic amphetamine and cocaine administration lead to an
accumulation of ΔfosB only in GABAergic neurons in the
VTA, and according to Perroti et al., ΔfosB accumulation
occurs only in neurons showing c-fos expression after acute
drug administration [39]. This in agreement with the evi-
dence supporting a key role for dopaminergic neurons in
VTA in the induction of sensitization;meanwhile, the expres-
sion is associated with neuroadaptations in CPu and Nacc
[1, 3]. When the total Fos immunoreactivity was analyzed
in VTA, there was found a decrease in Fos expression in
response to amphetamine challenge with respect to saline
challenge independently of the animal’s treatments (AT
1
receptor blocker or amphetamine).
The results in Fos expression obtained in VTA and
prelimbic cortex, showing no effect to pretreatment and
treatment, give a more specific role to the neuronal activation
in the amphetamine-induced neuroadaptative responses in
CPu and Nacc observed in the present study.
In conclusion, these results taken together with our
previous findings indicate that the development of behavioral
sensitization and altered neuronal activation induced by
amphetamine involve the AT
1
receptor activation. Since the
BioMed Research International 9
behavioral sensitization has been suggested as an adaptive
process in addiction to psychostimulant and other drugs of
abuse, it would be important to explore the brain AT
1
recep-
tors as a therapeutic target in drug abuse-related disorders.
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